Neurogene Inc.
NGNE
$16.80
-$0.98-5.51%
| Weiss Ratings | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 2.75% | |||
| 30-Day Total Return | 8.32% | |||
| 60-Day Total Return | -24.78% | |||
| 90-Day Total Return | -61.59% | |||
| Year to Date Total Return | -26.61% | |||
| 1-Year Total Return | -53.41% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -76.13% | |||
| 52-Week Low % Change | 23.30% | |||
| Price | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $74.49 | |||
| 52-Week Low Price | $14.42 | |||
| 52-Week Low Price (Date) | Jan 24, 2025 | |||
| 52-Week High Price (Date) | Nov 11, 2024 | |||
| Valuation | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 264.12M | |||
| Enterprise Value | 138.24M | |||
| Price/Earnings (TTM) | 0.40 | |||
| Earnings Per Share (TTM) | 43.96 | |||
| Earnings Per Share Growth | -148.95% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 326.24 | |||
| Price/Book (Q) | 1.68 | |||
| Enterprise Value/Revenue (TTM) | 149.45 | |||
| Price | $16.80 | |||
| Enterprise Value/EBITDA (TTM) | -1.91 | |||
| Enterprise Value/EBIT | -1.83 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 16.95M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 855 508 3568 | |||
| Address | 535 W 24th Street New York, NY 10011 | |||
| Website | www.neurogene.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -8,186.59% | |||
| Profit Margin | -5,756.43% | |||
| Management Effectiveness | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -39.75% | |||
| Return on Equity | -- | |||
| Income Statement | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 925.00K | |||
| Total Revenue (TTM) | 925.00K | |||
| Revenue Per Share | $0.06 | |||
| Gross Profit (TTM) | -56.73M | |||
| EBITDA (TTM) | -72.45M | |||
| EBIT (TTM) | -75.73M | |||
| Net Income (TTM) | -53.25M | |||
| Net Income Avl. to Common (TTM) | -53.25M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -38.69% | |||
| EPS Diluted (TTM) | 43.96 | |||
| EPS Diluted Growth (Q YOY) | 96.35% | |||
| Balance Sheet | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 138.99M | |||
| Cash Per Share (Q) | $8.20 | |||
| Total Current Assets (Q) | 143.65M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 137.41M | |||
| Current Ratio (Q) | 9.092 | |||
| Book Value Per Share (Q) | $10.56 | |||
| Total Assets (Q) | 164.12M | |||
| Total Current Liabilities (Q) | 15.80M | |||
| Total Debt (Q) | 13.12M | |||
| Total Liabilities (Q) | 26.71M | |||
| Total Common Equity (Q) | 137.41M | |||
| Cash Flow | NGNE - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 3.19M | |||
| Cash from Financing (TTM) | 88.30M | |||
| Net Change in Cash (TTM) | 21.41M | |||
| Levered Free Cash Flow (TTM) | -35.53M | |||
| Cash from Operations (TTM) | -70.08M | |||
